Bacillus Calmette–Guérin (BCG) Vaccines

Global Bacillus Calmette–Guérin (BCG) Vaccines Market to Reach US$113.3 Million by 2030

The global market for Bacillus Calmette–Guérin (BCG) Vaccines estimated at US$90.4 Million in the year 2024, is expected to reach US$113.3 Million by 2030, growing at a CAGR of 3.8% over the analysis period 2024-2030. Pediatrics, one of the segments analyzed in the report, is expected to record a 4.8% CAGR and reach US$60.3 Million by the end of the analysis period. Growth in the Adults segment is estimated at 2.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$24.6 Million While China is Forecast to Grow at 7.3% CAGR

The Bacillus Calmette–Guérin (BCG) Vaccines market in the U.S. is estimated at US$24.6 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$23.1 Million by the year 2030 trailing a CAGR of 7.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.5% and 3.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.2% CAGR.

Global Bacillus Calmette–Guérin (BCG) Vaccines Market – Key Trends & Drivers Summarized

Why Are BCG Vaccines Still Crucial in Combating Tuberculosis?

BCG vaccines remain one of the most important tools in the global fight against tuberculosis (TB), a disease that continues to pose a major public health challenge, particularly in low- and middle-income countries. First introduced nearly a century ago, the BCG vaccine has proven to be highly effective in preventing severe forms of TB, including meningitis and miliary TB, particularly in children. The vaccine is a cornerstone of national immunization programs in countries with high TB prevalence, where it plays a pivotal role in reducing childhood morbidity and mortality. Moreover, the vaccine’s protective effects against non-tuberculous mycobacterial infections and its potential benefits in preventing certain types of cancer, such as bladder cancer, have further solidified its importance. As global efforts to eliminate TB intensify, the World Health Organization (WHO) and other health organizations are prioritizing BCG vaccine distribution as part of their broader strategies to achieve health equity and control infectious diseases. Despite being an older vaccine, the continued relevance of BCG underscores its indispensable role in global health.

How Are Advancements in Production and Distribution Enhancing Vaccine Accessibility?

The BCG vaccine market has witnessed significant advancements in production and distribution infrastructure, ensuring that it remains accessible to populations in need. Manufacturers have been investing in modernized production techniques to enhance vaccine stability, shelf life, and scalability. For example, lyophilized (freeze-dried) formulations of the vaccine have made transportation and storage more convenient, especially in regions with limited cold-chain capabilities. The use of advanced biomanufacturing technologies has also enabled producers to scale up output, meeting the growing demand from national immunization programs. Additionally, global health initiatives, such as Gavi, the Vaccine Alliance, and UNICEF, have played a crucial role in improving vaccine procurement and distribution, particularly in resource-constrained settings. Collaborative partnerships between governments, non-governmental organizations, and pharmaceutical companies are ensuring that vaccines are delivered efficiently, even to remote or underserved areas. These advancements are helping to bridge the gap in vaccine equity, ensuring that the benefits of BCG reach vulnerable populations worldwide.

Which Factors Are Driving Regional Variations in BCG Vaccine Adoption?

The adoption of BCG vaccines varies widely across regions, influenced by local TB prevalence, healthcare infrastructure, and policy priorities. In high-burden regions such as Africa, South Asia, and parts of Southeast Asia, BCG vaccination is a mandatory part of national immunization schedules, reflecting the critical need to combat TB. These regions account for a significant share of the global vaccine demand due to their high population densities and relatively higher rates of TB transmission. Conversely, in low-burden countries such as the United States and much of Western Europe, BCG vaccination is typically reserved for specific high-risk groups, such as healthcare workers or individuals traveling to endemic areas. The vaccine is also gaining renewed attention in regions with growing concerns about drug-resistant TB strains, as it provides a preventive layer while more targeted interventions are developed. Regional variations in adoption are further shaped by public health policies, awareness campaigns, and the availability of funding for immunization programs. Understanding these dynamics is critical for aligning production and distribution strategies with local needs.

What Factors Are Propelling Growth in the BCG Vaccines Market?

The growth in the BCG vaccines market is driven by several factors, including the persistent prevalence of tuberculosis, advancements in vaccine manufacturing, and expanded immunization coverage. High TB burden regions continue to drive demand for BCG vaccines, as they form the first line of defense in national TB control programs. Innovations in vaccine production, such as lyophilized formulations and improved cold-chain logistics, have enhanced the scalability and reach of vaccination campaigns. Global health initiatives, supported by funding from organizations like WHO and Gavi, have also played a crucial role in expanding immunization coverage in low- and middle-income countries. Additionally, the vaccine’s role in preventing non-tuberculous diseases, such as bladder cancer, has created opportunities for its adoption in oncology. Rising awareness about drug-resistant TB strains has further highlighted the importance of preventive measures, boosting demand for BCG vaccines globally. Lastly, ongoing research into optimizing vaccine efficacy and exploring its potential in immunotherapy applications is creating new avenues for market growth, ensuring the continued relevance of this historic yet vital vaccine.

SCOPE OF STUDY:

The report analyzes the Bacillus Calmette–Guérin (BCG) Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Age Group (Pediatrics, Adults); Application (Tuberculosis Application, Bladder Cancer Application);End-Use (Hospitals End-Use, Clinics End-Use)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

• AJ Vaccines
• BB-NCIPD Ltd. (Bul Bio)
• BioFarma
• Biological E. Limited
• Bio-Manguinhos/Fiocruz
• Biomed-Lublin Wytwórnia Surowic i Szczepionek SA
• China National Pharmaceutical Group (Sinopharm)
• GreenSignal Bio Pharma Pvt. Ltd.
• Haffkine Bio-Pharmaceutical Corporation Ltd.
• InterVax Ltd.
• Japan BCG Laboratory
• Merck & Co., Inc.
• Microgen
• Sanofi Pasteur
• Serbia Torlak Institute
• Serum Institute of India Pvt. Ltd.
• Serum Institute of India Pvt. Ltd.
• Shantha Biotechnics Pvt. Ltd.
• Statens Serum Institut
• Vacsera

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.